Regentis to Begin European Surgeon Training for GelrinC in Q3 2026
Regentis Biomaterials Ltd. announced plans to commence European surgeon training for its GelrinC product in the third quarter of 2026. This initiative accelerates preparations for the commercial rollout of GelrinC in Europe, where it already holds CE Mark approval. The training program, designed to provide practical experience with the 10-minute implantation procedure, will begin in Milan, Italy, and expand to other European markets. GelrinC is positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, targeting a significant market opportunity.
Key Highlights
- Regentis to commence European surgeon training for GelrinC in Q3 2026.
- GelrinC, a cell-free hydrogel implant for knee cartilage repair, has CE Mark approval in the European Union.
- First training activities expected in Milan, Italy, at Humanitas Research Hospital.
- GelrinC procedure is a 10-minute, single-step implantation process.
- Company is establishing a network of European Centers of Excellence for surgeon education.
- Regentis targets an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases.
- Clinical data shows approximately 100% greater pain improvement versus standard microfracture.
- Pivotal U.S. FDA study for GelrinC has completed over 50% enrollment.
Price Impact
More from RGNT
Regentis Biomaterials Withdraws F-1 Registration for Public Offering
Regentis Biomaterials Ltd. Details Director Indemnification and Unregistered Securities Sales
Regentis Biomaterials Ltd. Announces Annual General Meeting on July 2, 2026